Sherman Chang

Dr. Chang joined AutoGenomics as Senior Director of R&D Chemistry in 2013 and was appointed as Vice President of R&D Chemistry in January 2016.  Prior to that, Dr. Chang was Senior Director of R&D at DermTech International (a biotech startup company in La Jolla, CA) where he developed a disruptive non-invasive melanoma cancer diagnostic test currently used in the market.  Dr. Chang brings over 20 years of experience in R&D and In Vitro Diagnostics (IVD).  Dr. Chang was the recipient of the 2017 AACC industry division poster award/certificate for genetic risk assessment of Opioid Addiction.  Dr. Chang holds a Pharmacy & M.S. in Biochemistry from National Taiwan University and a Ph.D. in Molecular Biology from University of Pittsburgh.  Dr. Chang completed his post-doctoral research training at the Salk Institute and UCSD.